GlassScriptPhysician profile
Emalee J Hanna
NPI 1619370392
$4,004.73
in general payments reported to CMS, 2019-2025
25 companies · $1,304 in 2025
The $1,304 reported for 2025 was more than what 85% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $267 · 2022: $513 · 2023: $792 · 2024: $1,128 · 2025: $1,304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,224.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,401.75 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $301.09 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Madrigal Pharmaceuticals | $145.27 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $122.76 | 2024-2025 | Iqirvo, Bylvay |
| Ardelyx, INC. | $122.12 | 2024-2025 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $107.14 | 2022 | |
| Genentech USA, INC. | $88.07 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.85 | 2022-2025 | Xifaxan |
| Lilly USA, LLC | $61.11 | 2024-2025 | Omvoh |
| Organon LLC | $60.52 | 2022-2025 | Hadlima |
| Celgene Corporation | $55.79 | 2022-2024 | Zeposia |
| Daiichi Sankyo INC. | $54.25 | 2022-2024 | Injectafer |
| Janssen Biotech, INC. | $53.36 | 2022-2024 | Simponi, Tremfya, Stelara |
| Qol Medical, LLC | $51.32 | 2022-2025 | Sucraid |
| Janssen Scientific Affairs, LLC | $50.84 | 2024-2025 | Tremfya |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $34.79 | 2024 | Voquezna |
| Pfizer INC. | $30.53 | 2024-2025 | |
| Novo Nordisk INC | $27.68 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $25.13 | 2023 | |
| Sandoz INC. | $24.50 | 2025 | Hyrimoz |
| Genzyme Corporation | $24.36 | 2023 | |
| Merck Sharp & Dohme LLC | $22.00 | 2021 | |
| Ferring Pharmaceuticals INC. | $21.41 | 2025 | Rebyota |
| Mallinckrodt Hospital Products INC. | $20.37 | 2024 | Terlivaz |
| Aimmune Therapeutics, INC. | $19.72 | 2025 | Vowst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emalee Hanna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.